These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21629663)

  • 1. Accelerated neuronal cell recovery from Botulinum neurotoxin intoxication by targeted ubiquitination.
    Kuo CL; Oyler GA; Shoemaker CB
    PLoS One; 2011; 6(5):e20352. PubMed ID: 21629663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Camelid VHH Antibodies that Neutralize Botulinum Neurotoxin Serotype E Intoxication or Protease Function.
    Tremblay JM; Vazquez-Cintron E; Lam KH; Mukherjee J; Bedenice D; Ondeck CA; Conroy MT; Bodt SML; Winner BM; Webb RP; Ichtchenko K; Jin R; McNutt PM; Shoemaker CB
    Toxins (Basel); 2020 Sep; 12(10):. PubMed ID: 32987745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system.
    Tsai YC; Maditz R; Kuo CL; Fishman PS; Shoemaker CB; Oyler GA; Weissman AM
    Proc Natl Acad Sci U S A; 2010 Sep; 107(38):16554-9. PubMed ID: 20823219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of Botulinum neurotoxin inactivation of nerve function.
    Shoemaker CB; Oyler GA
    Curr Top Microbiol Immunol; 2013; 364():179-96. PubMed ID: 23239354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
    Wang J; Zurawski TH; Bodeker MO; Meng J; Boddul S; Aoki KR; Dolly JO
    Biochem J; 2012 May; 444(1):59-67. PubMed ID: 22360156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases.
    Tremblay JM; Kuo CL; Abeijon C; Sepulveda J; Oyler G; Hu X; Jin MM; Shoemaker CB
    Toxicon; 2010 Nov; 56(6):990-8. PubMed ID: 20637220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid and cationic polymer based transduction of botulinum holotoxin, or toxin protease alone, extends the target cell range and improves the efficiency of intoxication.
    Kuo CL; Oyler G; Shoemaker CB
    Toxicon; 2010; 55(2-3):619-29. PubMed ID: 19852976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication.
    Tsai YC; Kotiya A; Kiris E; Yang M; Bavari S; Tessarollo L; Oyler GA; Weissman AM
    Proc Natl Acad Sci U S A; 2017 Jun; 114(26):E5158-E5166. PubMed ID: 28584101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin.
    Edupuganti OP; Ovsepian SV; Wang J; Zurawski TH; Schmidt JJ; Smith L; Lawrence GW; Dolly JO
    FEBS J; 2012 Jul; 279(14):2555-67. PubMed ID: 22607388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A yeast assay probes the interaction between botulinum neurotoxin serotype B and its SNARE substrate.
    Fang H; Luo W; Henkel J; Barbieri J; Green N
    Proc Natl Acad Sci U S A; 2006 May; 103(18):6958-63. PubMed ID: 16636286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions.
    Ayyar BV; Aoki KR; Atassi MZ
    Infect Immun; 2015 Apr; 83(4):1465-76. PubMed ID: 25624352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.
    Adler M; Keller JE; Sheridan RE; Deshpande SS
    Toxicon; 2001; 39(2-3):233-43. PubMed ID: 10978741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
    Höltje M; Schulze S; Strotmeier J; Mahrhold S; Richter K; Binz T; Bigalke H; Ahnert-Hilger G; Rummel A
    Toxicon; 2013 Dec; 75():108-21. PubMed ID: 23817019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B.
    Fan Y; Dong J; Lou J; Wen W; Conrad F; Geren IN; Garcia-Rodriguez C; Smith TJ; Smith LA; Ho M; Pires-Alves M; Wilson BA; Marks JD
    Toxins (Basel); 2015 Aug; 7(9):3405-23. PubMed ID: 26343720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two VHH Antibodies Neutralize Botulinum Neurotoxin E1 by Blocking Its Membrane Translocation in Host Cells.
    Lam KH; Perry K; Shoemaker CB; Jin R
    Toxins (Basel); 2020 Sep; 12(10):. PubMed ID: 32992561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin.
    Patel KB; Cai S; Adler M; Singh BK; Parmar VS; Singh BR
    Appl Environ Microbiol; 2018 Dec; 84(24):. PubMed ID: 30389764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics.
    Wang J; Meng J; Lawrence GW; Zurawski TH; Sasse A; Bodeker MO; Gilmore MA; Fernández-Salas E; Francis J; Steward LE; Aoki KR; Dolly JO
    J Biol Chem; 2008 Jun; 283(25):16993-7002. PubMed ID: 18400760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons.
    Foran PG; Mohammed N; Lisk GO; Nagwaney S; Lawrence GW; Johnson E; Smith L; Aoki KR; Dolly JO
    J Biol Chem; 2003 Jan; 278(2):1363-71. PubMed ID: 12381720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis.
    Wang J; Zurawski TH; Meng J; Lawrence GW; Aoki KR; Wheeler L; Dolly JO
    FASEB J; 2012 Dec; 26(12):5035-48. PubMed ID: 22942075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat shock protein 70 overexpression does not attenuate atrophy in botulinum neurotoxin type A-treated skeletal muscle.
    Houston FE; Hain BA; Adams TJ; Houston KL; O'Keeffe R; Dodd SL
    J Appl Physiol (1985); 2015 Jul; 119(1):83-92. PubMed ID: 25953835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.